|
Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >
(2) GLP-1受容体作動薬 （III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬）
| Title: | (2) GLP-1受容体作動薬 （III. 糖尿病治療薬に関する最近の話題 3. インクレチン関連薬） |
| Authors: | 三好, 秀明1 Browse this author →KAKEN DB |
| Authors(alt): | Miyoshi, Hideaki1 |
| Keywords: | GLP-1 receptor agonist | | diabetes | | cardiovascular outcome |
| Issue Date: | 1-Jul-2020 |
| Publisher: | 日本臨牀社 |
| Journal Title: | 日本臨牀 |
| Journal Title(alt): | Japanese journal of clinical medicine |
| Volume: | 78 |
| Issue: | 7 |
| Start Page: | 1139 |
| End Page: | 1145 |
| Abstract: | Glucagon-like peptide-1 receptor agonists (GLP-1RAs) demonstrate hypoglycemic effects with decreasing daily glycemic variability via plasma glucose-dependent insulin secretion and glucagon suppression, and delayed gastric emptying. GLP-1RAs also reduce appetite via the central nervous system, resulting in body weight reduction. There are many other targets of GLP-1RAs reported recently such as heart, kidney, and liver. Importantly, large cardiovascular outcomes trials revealed and confirmed that GLP-1RAs reduced major adverse cardiovascular events, cardiovascular death, and chronic kidney disease progression. The priority and frequency of use of GLP-1RAs among the antihyperglycemic agents are increasing worldwide. Moreover, new kinds of GLP-1RAs, which are expected to further reduce HbA1c and body weight, will be available in the near future. |
| Type: | article |
| URI: | http://hdl.handle.net/2115/78867 |
| Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|
Submitter: 三好 秀明
|
